Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer

References 

1. Hall E. Radiobiology for the radiologist. 4th ed.. Philadelphia: JB Lippincott; 1994;
2. Marks R, Witherspoon B, Davis L. Hyperfractionation—Where we stand—A preliminary RTOG report. Proc Am Soc Ther Radiol. 1978;4:139–140
3. Seydel H, Deiner-West M, Urtasun R. Hyperfractionation in radiation therapy of unresectable non-oat cell carcinoma of the lung (Preliminary report of a RTOG pilot study). Int J Radiat Oncol Biol Phys. 1985;11:1841–1847
   • Abstract
   • Full-Text PDF (858 KB)
   • CrossRef
4. Cox JD, Azarnia N, Byhardt RW, et al.  A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy (Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma—Report of Radiation Therapy Oncology Group 83-11). J Clin Oncol. 1990;8:1543–1555
   • MEDLINE
5. Sause WT, Scott C, Taylor S, et al.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588 (Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer). J Nat Cancer Inst. 1995;87:198–205
6. Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group Komaki R, Scott CB, Sause WT, et al.  Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer (Failure patterns by cell type in RTOG 88-08/ECOG 4588). Int J Radiat Oncol Biol Phys. 1997;39:537–544
   • Full-Text PDF (733 KB)
   • CrossRef
7. CHART Steering Committee Saunders MI, Dische S, Barrett A, et al.  Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer (An interim report). Br J Cancer. 1996;73:1455–1462
   • MEDLINE
8. CHART Steering Committee Saunders MI, Dische S, Barrett A, et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer (Mature data from the randomized multicentre trial). Radiother Oncol. 1999;52:137–148
   • Abstract
   • Full Text
   • Full-Text PDF (209 KB)
   • CrossRef
9. Schaake-Konning C, Van Den Bogaert W, Dalesio O, et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
   • MEDLINE
   • CrossRef
10. Jeremic B, Shibamoto Y, Acimovic L, et al.  Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol. 1995;13:452–458
    • MEDLINE
11. Jeremic B, Shibamoto Y, Acimovic L, et al.  Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer (A randomized study). J Clin Oncol. 1996;14:1065–1070
    • MEDLINE
12. Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In:  CM M editors. Evaluation of chemotherapeutic agents. Symposium, Microbiology Section, New York Academy of Medicine. New York: Columbia University Press; 1949;p. 191–205
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
    • MEDLINE
15. Cox D. Regression models and life tables. J R Stat Soc, Series B. 1972;34:187–229
16. Bonner J, McGinnis W, Stella P, et al.  The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung carcinoma (Results of a North Center Cancer Treatment Group phase III study). Cancer. 997;82:1037–1048
    • MEDLINE
    • CrossRef
17. Perez CA, Stanley K, Rubin P, et al.  A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung (Preliminary report by the Radiation Therapy Oncology Group). Cancer. 1980;45:2744–2753
    • MEDLINE
    • CrossRef
18. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors (Overview of the randomized clinical trials). Int J Radiat Oncol Biol Phys. 1997;37:259–267
    • Abstract
    • Full-Text PDF (1078 KB)
    • CrossRef
19. Marino P, Preatoni A, Cantoni A. Randomized trials of therapy in Stages IIIa and IIIb nonsmall cell lung cancer. Cancer. 1995;76:593–601
    • MEDLINE
    • CrossRef
20. Curran WJ. Sequential versus concurrent chemoradiation in unresected stage III NSCLC (RTOG 94-10 initial report). Proceedings of ASCO. 2000;19:484a
21. Komaki R, Seiferheld W, Curran WJ, et al.  Sequential versus concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC) (Analysis of failures in a phase III study (RTOG 9410). Proceedings of the 42nd Annual Meeting of ASTRO, Boston, MA, 2000). Int J Radiat Oncol Biol Phys. 2000;48(Abstr.):S113
22. Stella P, Marks R, Schild S, et al.  In: Phase III trial of chemotherapy plus either standard radiotherapy (QD-RT) or accelerated hyperfractionated thoracic radiotherapy (AHTRT) for stage III non-small cell lung cancer (NSCLC). San Francisco, CA: Proceedings of the 37th Annual Meeting of ASCO; 2001;p. 312a
23. Lee JS, Scott C, Komaki R, et al.  Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer (Radiation Therapy Oncology Group protocol 91-06). J Clin Oncol. 1996;14:1055–1064
    • MEDLINE
24. Furuse K, Fukuoka M, Kawahara M, et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;17:2692–2699
    • MEDLINE